NeoGenomics

ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights

Retrieved on: 
Thursday, March 28, 2024
Research, IL-17A, Strategic planning, Cell, Exophthalmos, Disease, Infection, Fungus, Risk, Inflammation, SLRN, Patient, Psoriatic arthritis, Acquisition, Doctor of Philosophy, MD, Quality of life, CAS, Senior, IPR, Eye, NeoGenomics, Graves' ophthalmopathy, Suicidal ideation, Behavior, Hidradenitis suppurativa, QW, Drug development, LOS, Corporate communication, Abscess, Diplopia, Pharmaceutical industry

LOS ANGELES, March 28, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the full year ended December 31, 2023 and highlighted recent corporate updates and upcoming milestones.

Key Points: 
  • R&D Expenses: Research and development expenses were $355.9 million for the full year ended December 31, 2023, as compared to $55.6 million for 2022.
  • G&A Expenses: General and administrative expenses were $66.2 million for the full year ended December 31, 2023, as compared to $13.5 million for 2022.
  • Net Loss: Net loss for the full year ended December 31, 2023 was $381.6 million, compared to $64.8 million for 2022.
  • In December 2023, the Company announced the appointment of Lynn Tetrault to its Board of Directors.

NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024

Retrieved on: 
Tuesday, April 9, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, NEO, NeoGenomics, Telephone, Webcast

NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its first quarter 2024 financial results on Tuesday, April 30, 2024.

Key Points: 
  • NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its first quarter 2024 financial results on Tuesday, April 30, 2024.
  • Company management will host a webcast and conference call that morning at 8:30 a.m. Eastern Time to discuss financial results and recent highlights.
  • The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com .
  • To access the live call via telephone, dial (877) 545-0523 (domestic) or (973) 528-0016 (international) at least five minutes prior to the call.

NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference

Retrieved on: 
Friday, March 1, 2024
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Other Science, Research, Medical Devices, Infectious Diseases, General Health, Genetics, Science, Nursing, Medical Supplies, NEO, NeoGenomics, Conference

NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced the company will participate in the upcoming TD Cowen 44th Annual Health Care Conference in Boston, Massachusetts.

Key Points: 
  • NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced the company will participate in the upcoming TD Cowen 44th Annual Health Care Conference in Boston, Massachusetts.
  • Members of NeoGenomics’ management team will participate in a fireside chat on Tuesday, March 5th at 9:10 a.m.
  • ET.
  • A live and archived audio webcast of the presentation will be available on the “News, Events, and Webcasts” tab via the Investor Relations section of the Company’s website at ir.neogenomics.com .

NeoGenomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20, 2024

Retrieved on: 
Tuesday, January 30, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Telephone, NeoGenomics, Webcast, NEO

NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 20, 2024.

Key Points: 
  • NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 20, 2024.
  • Company management will host a webcast and conference call that day at 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
  • The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com .
  • To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. - NEO

Retrieved on: 
Friday, January 26, 2024
Pomerantz, Patient, Prior, NeoGenomics, Radar, News

NEW YORK, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO).

Key Points: 
  • NEW YORK, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO).
  • The investigation concerns whether NeoGenomics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. - NEO

Retrieved on: 
Thursday, January 18, 2024
Pomerantz, Patient, Prior, NeoGenomics, Radar, News

NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO).

Key Points: 
  • NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO).
  • The investigation concerns whether NeoGenomics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. - NEO

Retrieved on: 
Wednesday, January 10, 2024
Pomerantz, Patient, NeoGenomics, Radar, News

NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO).

Key Points: 
  • NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO).
  • The investigation concerns whether NeoGenomics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

NeoGenomics and ConcertAI Announce Collaboration to Advance Population-Scale, Definitive Hematological Research & Generative AI Solutions at ASH 2023

Retrieved on: 
Monday, January 8, 2024
Clinical trial, Gasparini, Collection, Research, FDA, Data, Doctor of Philosophy, Artificial intelligence, EMR, AI, Cytogenetics, Biomarker, Hematology, Patient, Diagnosis, NeoGenomics, Selection bias, Bone marrow, Flow cytometry, RWE, Medical imaging

Hematological malignancies require surveillance of patients over multiple time periods with numerous clinical and diagnostic measures to assess sustained response to treatment or relapse.

Key Points: 
  • Hematological malignancies require surveillance of patients over multiple time periods with numerous clinical and diagnostic measures to assess sustained response to treatment or relapse.
  • Combining ConcertAI's longitudinal clinical data with NeoGenomics' comprehensive biomarkers derived from hundreds of hematological tests we are able to establishe a robust and definitive RWE hematology solution.
  • The collaboration advances molecular and genetic data solutions for the entire drug development lifecycle, from early clinical development to post-approval epidemiological studies.
  • "ConcertAI has spent the last three years with biopharma researchers, medical societies, patient advocacy groups, and academic teams to define requirements for truly definitive, insight-enabling research solutions for hematological malignancies," said Jeff Elton, PhD, CEO of ConcertAI.

ROSEN, A LEADING NATIONAL FIRM, Encourages NeoGenomics, Inc. Investors to Inquire About Securities Class Action Investigation – NEO

Retrieved on: 
Tuesday, January 2, 2024
Class Action Lawsuit, Professional Services, Legal, Titan, NEO, NeoGenomics, Radar, News, Advertising, Patient, Cryptocurrency

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=21558 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=21558 or call Phillip Kim, Esq.
  • toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. - NEO

Retrieved on: 
Tuesday, January 2, 2024
Radar, News, Pomerantz, Patient, NeoGenomics

NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO).

Key Points: 
  • NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO).
  • The investigation concerns whether NeoGenomics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.